Antev
Phase 1Antev is a clinical stage biotech developing Teverelix as first in market product for high CV risk prostate cancer patients & patients with first Acute Urinary Retention (AUR) episode due to enlarged prostate
Founded
2021
Focus
Small Molecules
About
Antev is a clinical stage biotech developing Teverelix as first in market product for high CV risk prostate cancer patients & patients with first Acute Urinary Retention (AUR) episode due to enlarged prostate
Funding History
1Total raised: $3.2M
Seed$3.2MUndisclosedJan 15, 2023
Company Info
TypePrivate
Founded2021
LocationLondon, United Kingdom
StagePhase 1
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile